

Nigel D Toussaint

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3761807/publications.pdf>

Version: 2024-02-01

91
papers

3,052
citations

279487

23
h-index

168136

53
g-index

101
all docs

101
docs citations

101
times ranked

3925
citing authors

#	ARTICLE	IF	CITATIONS
1	Executive summary of the 2017 KDIGO Chronic Kidney Disease "Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. <i>Kidney International</i> , 2017, 92, 26-36.	2.6	698
2	Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. <i>Kidney International</i> , 2019, 95, 160-172.	2.6	277
3	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease "Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. <i>Annals of Internal Medicine</i> , 2018, 168, 422.	2.0	228
4	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 586-593.	0.4	214
5	Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 221-233.	2.2	117
6	Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. <i>Nephrology</i> , 2011, 16, 290-298.	0.7	109
7	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2010, 56, 57-68.	2.1	99
8	Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients. <i>Hemodialysis International</i> , 2008, 12, 254-263.	0.4	79
9	Temporal distribution of arrhythmic events in chronic kidney disease: Highest incidence in the long interdialytic period. <i>Heart Rhythm</i> , 2015, 12, 2047-2055.	0.3	79
10	Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. <i>Nephrology</i> , 2007, 12, 500-509.	0.7	71
11	Review of dialysate calcium concentration in hemodialysis. <i>Hemodialysis International</i> , 2006, 10, 326-337.	0.4	60
12	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2653-2666.	3.0	52
13	Chronic Kidney Disease and Pulse Wave Velocity: A Narrative Review. <i>International Journal of Hypertension</i> , 2019, 2019, 1-11.	0.5	44
14	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. <i>Nephrology</i> , 2012, 17, 433-444.	0.7	42
15	Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. <i>Seminars in Dialysis</i> , 2018, 31, 487-499.	0.7	40
16	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1319-1326.	0.4	39
17	Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. <i>American Journal of Nephrology</i> , 2018, 47, 376-384.	1.4	39
18	Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 119-127.	2.2	38

#	ARTICLE	IF	CITATIONS
19	A trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in Hemodialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020, 49, 468-478.	0.9	38
20	Relationship between vascular calcification, arterial stiffness and bone mineral density in a cross-sectional study of prevalent Australian haemodialysis patients. <i>Nephrology</i> , 2009, 14, 105-112.	0.7	35
21	Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1011-1032.	3.0	32
22	Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. <i>Bone</i> , 2018, 114, 14-21.	1.4	26
23	Lateral lumbar X-ray assessment of abdominal aortic calcification in Australian haemodialysis patients. <i>Nephrology</i> , 2011, 16, 389-395.	0.7	25
24	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	0.8	25
25	Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2020, 51, 201-215.	1.4	24
26	High-intensity physical exercise increases serum κ -klotho levels in healthy volunteers. <i>Journal of Circulating Biomarkers</i> , 2018, 7, 184945441879458.	0.8	23
27	Improving medication adherence in adult kidney transplantation (IMAKT): A pilot randomised controlled trial. <i>Scientific Reports</i> , 2019, 9, 7734.	1.6	20
28	Implementation of renal key performance indicators: Promoting improved clinical practice. <i>Nephrology</i> , 2015, 20, 184-193.	0.7	19
29	The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 649-656.	0.4	19
30	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019, 9, e024382.	0.8	18
31	Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 619-627.	0.4	17
32	Mineral adaptations following kidney transplantation. <i>Transplant International</i> , 2017, 30, 463-473.	0.8	16
33	Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. <i>BMC Nephrology</i> , 2018, 19, 113.	0.8	16
34	Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 59-76.	3.0	16
35	Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. <i>Hemodialysis International</i> , 2007, 11, 217-224.	0.4	15
36	Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial. <i>Kidney International Reports</i> , 2020, 5, 1432-1447.	0.4	15

#	ARTICLE	IF	CITATIONS
37	Epidemiology and Outcomes of Acute Kidney Diseases: A Comparative Analysis. American Journal of Nephrology, 2021, 52, 342-350.	1.4	15
38	Measurement of vascular calcification using CT fistulograms. Nephrology Dialysis Transplantation, 2006, 22, 484-490.	0.4	14
39	Extracellular matrix calcification in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2011, 20, 360-368.	1.0	14
40	Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?. Nephrology, 2017, 22, 51-56.	0.7	14
41	Risk factors for major adverse kidney events in the first year after acute kidney injury. CKJ: Clinical Kidney Journal, 2021, 14, 556-563.	1.4	13
42	Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Scientific Reports, 2022, 12, 7358.	1.6	13
43	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. Nephrology, 2010, 15, 575-583.	0.7	12
44	Nephrology training in Australia and New Zealand: A survey of outcomes and adequacy. Nephrology, 2017, 22, 35-42.	0.7	12
45	Soluble klotho may be a marker of phosphate reabsorption. CKJ: Clinical Kidney Journal, 2017, 10, 397-404.	1.4	12
46	Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Nephrology, 2011, 16, 113-117.	0.7	10
47	Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?. Nephrology, 2017, 22, 36-41.	0.7	10
48	Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodialysis International, 2021, 25, 322-332.	0.4	10
49	Haemorrhagic Campylobacter jejuni and CMV colitis in a renal transplant recipient. Nephrology Dialysis Transplantation, 2005, 20, 823-826.	0.4	9
50	Relationship between timed and spot urine collections for measuring phosphate excretion. International Urology and Nephrology, 2016, 48, 115-124.	0.6	9
51	Changes in bone microarchitecture following kidney transplantation—Beyond bone mineral density. Clinical Transplantation, 2018, 32, e13347.	0.8	9
52	Outcomes of cinacalcet withdrawal in Australian dialysis patients. Internal Medicine Journal, 2019, 49, 48-54.	0.5	9
53	Diurnal variation and short-term pre-analytical stability of serum soluble β -klotho in healthy volunteers: a pilot study. Annals of Clinical Biochemistry, 2015, 52, 506-509.	0.8	8
54	Emerging role of high-resolution imaging in the detection of renal osteodystrophy. Nephrology, 2016, 21, 801-811.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Review: Differences in prescription between conventional and alternative haemodialysis. <i>Nephrology</i> , 2010, 15, 399-405.	0.7	7
56	Introduction of Renal Key Performance Indicators Associated with Increased Uptake of Peritoneal Dialysis in a Publicly Funded Health Service. <i>Peritoneal Dialysis International</i> , 2017, 37, 198-204.	1.1	7
57	Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. <i>BMC Nephrology</i> , 2019, 20, 258.	0.8	7
58	Impact of cinacalcet pre-€transplantation on mineral metabolism in renal transplant recipients. <i>Nephrology</i> , 2016, 21, 46-54.	0.7	6
59	Gram-negative sepsis following biopsy of a transplant recipient with asymptomatic allograft pyelonephritis. <i>CEN Case Reports</i> , 2017, 6, 46-49.	0.5	6
60	Changes in Markers of Mineral Metabolism After Living Kidney Donation. <i>Transplantation Direct</i> , 2017, 3, e150.	0.8	6
61	Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. <i>Hemodialysis International</i> , 2017, 21, 19-28.	0.4	6
62	Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease. <i>BMC Nephrology</i> , 2020, 21, 279.	0.8	6
63	Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand. <i>Nephrology</i> , 2021, 26, 814-823.	0.7	6
64	Bone microarchitecture and estimated failure load are deteriorated whether patients with chronic kidney disease have normal bone mineral density, osteopenia or osteoporosis. <i>Bone</i> , 2022, 154, 116260.	1.4	6
65	Efficacy of a non-vancomycin-based peritoneal dialysis peritonitis protocol. <i>Nephrology</i> , 2005, 10, 142-146.	0.7	5
66	Nephrologists' management of patient medications in kidney transplantation: results of an online survey. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 879-885.	0.9	5
67	What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1377-1379.	2.2	5
68	Community acquired versus Hospital acquired acute kidney injury at a large Australian metropolitan quaternary referral centre – incidence, associations, and outcomes. <i>Internal Medicine Journal</i> , 2022, , .	0.5	5
69	Is Nutritional Vitamin D Supplementation Beneficial in Dialysis Patients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 544-546.	2.2	4
70	Magnetic resonance imaging determination of tissue sodium in patients with chronic kidney disease. <i>Nephrology</i> , 2022, 27, 117-125.	0.7	4
71	Total Body Sodium Balance in Chronic Kidney Disease. <i>International Journal of Nephrology</i> , 2021, 2021, 1-10.	0.7	4
72	Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease. , 2022, 32, 58-67.		4

#	ARTICLE	IF	CITATIONS
73	A patient with Henoch-Schonlein purpura and intra-alveolar haemorrhage. CKJ: Clinical Kidney Journal, 2008, 1, 167-170.	1.4	3
74	Is there a practical role for a virtual bone biopsy using high-resolution imaging of bone in patients with chronic kidney disease?. Nephrology, 2017, 22, 27-30.	0.7	3
75	Bone microarchitecture in patients undergoing parathyroidectomy for management of secondary hyperparathyroidism. Bone Reports, 2020, 13, 100297.	0.2	3
76	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. Journal of Diabetes Research, 2022, 2022, 1-12.	1.0	3
77	The burden of fractures, vascular pathology and mortality in chronic kidney disease—mineral and bone disorders. Nephrology, 2017, 22, 9-10.	0.7	2
78	Hip fractures in patients with chronic kidney disease admitted to Victorian hospitals. Internal Medicine Journal, 2019, 49, 658-661.	0.5	2
79	Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease. , 2021, 31, 155-163.		2
80	Changes in bone microarchitecture following parathyroidectomy in patients with secondary hyperparathyroidism. Bone Reports, 2021, 15, 101120.	0.2	2
81	Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3–4 CKD—results from a placebo-controlled randomized trial. Nephrology Dialysis Transplantation, 2023, 38, 344-351.	0.4	2
82	Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers. Journal of the American Society of Nephrology: JASN, 2019, 30, 909-910.	3.0	1
83	Hospitalized fracture rates amongst patients with chronic kidney disease in Australia using data linkage. Nephrology, 2020, 25, 475-482.	0.7	1
84	Practice patterns and predictors of outpatient care following acute kidney injury in an Australian healthcare setting. Internal Medicine Journal, 2022, 52, 79-88.	0.5	1
85	Electronic alerts for early detection of acute kidney injury: considering their implementation in Australian hospitals. Medical Journal of Australia, 2021, 214, 347.	0.8	1
86	Outcomes following parathyroidectomy for secondary hyperparathyroidism in patients with chronic kidney disease—a single-centre study. Internal Medicine Journal, 2021, , .	0.5	1
87	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
88	FP249LONG TERM SEQUELAE OF ACUTE KIDNEY INJURY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES USING CONSENSUS DEFINITIONS OF EXPOSURE. Nephrology Dialysis Transplantation, 2018, 33, i114-i114.	0.4	0
89	Residual kidney function in nocturnal vs conventional haemodialysis patients: a prospective observational study. International Urology and Nephrology, 2020, 52, 757-764.	0.6	0
90	Muddying the waters of hyperparathyroidism management in chronic kidney disease: a brown tumour in a predialysis patient. Internal Medicine Journal, 2021, 51, 450-451.	0.5	0

#	ARTICLE	IF	CITATIONS
91	MO722PHOSPHATE-BINDER THERAPY WITH SUCROFERRIC OXYHYDROXIDE REDUCES ENDOGENOUS CALCIPROTEIN PARTICLE FORMATION AND CRYSTALLIZATION IN A POST-HOC ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0